公开(公告)号：US20180245119A1

公开(公告)日：2018-08-30

申请号：US15971233

申请日：2018-05-04

Applicant: Synaffix B.V.

Inventor： Sander Sebastiaan Van Berkel ,  Remon Van Geel ,  Maria Antonia Wijdeven ,  Floris Louis Van Delft

IPC: C12P21/00 ,  C07K16/32 ,  C12N9/10 ,  C07K16/28

CPC classification number: C12P21/005 ,  A61K47/61 ,  A61K47/64 ,  A61K47/6803 ,  A61K47/6849 ,  C07K16/2878 ,  C07K16/32 ,  C07K2317/14 ,  C07K2317/41 ,  C12N9/1051 ,  C12Y204/01038 ,  C12Y204/01092

Abstract: The present invention relates to a process for the enzymatic modification of a glycoprotein. The process comprises the step of contacting a glycoprotein comprising a glycan comprising a terminal GlcNAc-moiety, in the presence of glycosyltransferase that is, or is derived from, a β-(1,4)-N-acetylgalactosaminyltransferase, with a non-natural sugar-derivative nucleotide. The non-natural sugar-derivative nucleotide is according to formula (3): wherein A is selected from the group consisting of —N3, —C(O)R3, —(CH2)iC≡C—R4, —SH, —SC(O)R8, —SC(O)OR8, —SC(S)OR8, —F, —Cl, —Br —I, —OS(O)2R5, terminal C2-C24 alkenyl groups, C3-C5 cycloalkenyl groups, C4-C8 alkadienyl groups, terminal C3-C24 allenyl groups and amino groups. The invention further relates to a glycoprotein obtainable by the process according to the invention, to a bioconjugate that can be obtained by conjugating the glycoprotein with a linker-conjugate, and to β-(1,4)-N-acetylgalactosaminyltransferases that can be used in preparing the glycoprotein according to the invention.

公开(公告)号：US20180244787A1

公开(公告)日：2018-08-30

申请号：US15851651

申请日：2017-12-21

Applicant: SANOFI ,  UNIVERSITY OF MASSACHUSETTS

Inventor： William H. Brondyk ,  Ruiyin Chu ,  Timothy D. Connors ,  Sunghae Park ,  Huawei Qiu ,  Michele Youd ,  John Harris ,  Jillian Richmond

IPC: C07K16/28 ,  A61P17/00

CPC classification number: C07K16/2866 ,  A61K2039/505 ,  A61P17/00 ,  A61P37/00 ,  C07K2317/14 ,  C07K2317/24 ,  C07K2317/41 ,  C07K2317/52 ,  C07K2317/56 ,  C07K2317/565 ,  C07K2317/72 ,  C07K2317/732 ,  C07K2317/734 ,  C07K2317/92 ,  C07K2317/94

Abstract: Provided are methods and uses of anti-CXCR3 antibodies to treat CXCR3-associated disorders such as vitiligo. In certain embodiments, the anti-CXCR3 antibodies are humanized anti-human CXCR3 antibodies with enhanced effector function against cells expressing CXCR3 on their surface.

公开(公告)号：US10059777B2

公开(公告)日：2018-08-28

申请号：US14390755

申请日：2013-04-05

Applicant: Gottfried Himmler

Inventor： Gottfried Himmler

IPC: C07K16/44 ,  C07K16/04 ,  C07K16/12 ,  C07K16/30 ,  A61K39/00 ,  A61K38/00

CPC classification number: C07K16/44 ,  A61K38/00 ,  A61K2039/541 ,  C07K16/04 ,  C07K16/1282 ,  C07K16/3076 ,  C07K2317/14 ,  C07K2317/30 ,  C07K2317/31 ,  C07K2317/40 ,  C07K2317/41 ,  C07K2319/036

Abstract: The invention provides a method of producing an immune complex preparation based on a secretory immunoglobulin, which is non-human secretion derived, comprising providing an industrial scale production system, capable of producing an N-glycosylated Secretory Component, producing by such system a Secretory Component comprising at least 0.01 mol non-core fucose per mol Secretory Component, and combining said Secretory Component with at least one of IgA or IgM immunoglobulins having a native glycosylation pattern to obtain an immune complex. The invention provides an isolated recombinant Secretory Component comprising the amino acid sequence of SEQ ID 1, or a functionally active variant thereof, which has a Lewis-type N-glucosylation pattern and at least 2 mol non-core fucose per mol Secretory Component; and an immune complex preparation based on a secretory immunoglobulin, derived from sources other than human secretions, comprising a Secretory Component with a Lewis-type N-glucosylation pattern and at least 0.01 mol non-core fucose per mol Secretory Component, and at least one of IgA or IgM immunoglobulins having a native glycosylation pattern.

公开(公告)号：US10040851B2

公开(公告)日：2018-08-07

申请号：US14968098

申请日：2015-12-14

Applicant: ALDERBIO HOLDINGS LLC

Inventor： Jeffrey T. L. Smith

IPC: C07K16/24 ,  A61K39/395 ,  A61K45/06 ,  A61K39/00

CPC classification number: C07K16/248 ,  A61K39/395 ,  A61K39/3955 ,  A61K45/06 ,  A61K2039/505 ,  C07K2316/96 ,  C07K2317/24 ,  C07K2317/34 ,  C07K2317/41 ,  C07K2317/56 ,  C07K2317/565 ,  C07K2317/76 ,  C07K2317/92 ,  G01N2333/4737 ,  G01N2333/765 ,  G01N2800/52

Abstract: The present invention is directed to therapeutic methods using IL-6 antagonists such as antibodies and fragments thereof having binding specificity for IL-6 to improve survivability or quality of life of a patient in need thereof. In preferred embodiments these patients will comprise those exhibiting (or at risk of developing) an elevated serum C-reactive protein level or a reduced serum albumin level prior to treatment. In another preferred embodiment, the patient's Glasgow Prognostic Score will be increased and survivability will preferably be improved.

公开(公告)号：US10040849B2

公开(公告)日：2018-08-07

申请号：US14115784

申请日：2012-05-08

Applicant: David Gearing

Inventor： David Gearing

IPC: C07K16/22 ,  C07K16/46 ,  A61K39/395 ,  A61K45/06

CPC classification number: C07K16/22 ,  A61K39/3955 ,  A61K45/06 ,  C07K16/467 ,  C07K2317/24 ,  C07K2317/41 ,  C07K2317/71 ,  C07K2317/72 ,  C07K2317/734

Abstract: A method of preparing an antibody suitable for use in a canine is provided. Also provided are caninized antibodies which specifically bind to canine neuronal growth factor (NGF) and neutralize the ability of canine NGF to bind to the p75 or TrkA canine NGF receptor. The invention extends to nucleic acids encoding same and to methods of treating pain and arthritis in a canine using said antibodies and/or nucleic acids.

公开(公告)号：US10040845B2

公开(公告)日：2018-08-07

申请号：US15716818

申请日：2017-09-27

Applicant: Institute for Research in Biomedicine

Inventor： Antonio Lanzavecchia ,  Annalisa Macagno

IPC: A01D34/71 ,  A61K38/00 ,  A61K39/00 ,  A61K39/42 ,  A01D34/63 ,  C07K14/005 ,  C07K16/08 ,  A01D101/00

CPC classification number: C07K16/088 ,  A01D34/63 ,  A01D34/71 ,  A01D2101/00 ,  A61K38/00 ,  A61K39/00 ,  A61K39/42 ,  A61K2039/505 ,  A61K2039/507 ,  C07K14/005 ,  C07K2317/21 ,  C07K2317/34 ,  C07K2317/41 ,  C07K2317/54 ,  C07K2317/55 ,  C07K2317/56 ,  C07K2317/565 ,  C07K2317/622 ,  C07K2317/76 ,  C07K2317/92 ,  C12N2710/16122

Abstract: The invention relates to neutralizing antibodies, and antibody fragments thereof, having high potency in neutralizing hCMV, wherein said antibodies and antibody fragments are specific for one, or a combination of two or more, hCMV gene UL products. The invention also relates to immortalized B cells that produce, and to epitopes that bind to, such antibodies and antibody fragments. In addition, the invention relates to the use of the antibodies, antibody fragments, and epitopes in screening methods as well as in the diagnosis, prevention, and therapy of disease.

公开(公告)号：US20180215810A1

公开(公告)日：2018-08-02

申请号：US15928566

申请日：2018-03-22

Applicant: Merck Sharp & Dahme Corp.

Inventor： Kalpit A. Vora ,  Kara S. Cox ,  Aimin Tang ,  Zhifeng Chen ,  Daniel DiStefano ,  Lan Zhang ,  Hua-Poo Su

IPC: C07K16/10 ,  A61K39/42 ,  A61K39/00

CPC classification number: C07K16/1027 ,  A61K39/42 ,  A61K2039/505 ,  A61K2039/54 ,  A61K2039/545 ,  C07K2317/14 ,  C07K2317/21 ,  C07K2317/34 ,  C07K2317/41 ,  C07K2317/524 ,  C07K2317/565 ,  C07K2317/732 ,  C07K2317/76 ,  C07K2317/92 ,  C07K2317/94

Abstract: The present invention relates to monoclonal antibodies which have high anti-RSV neutralizing titers. The invention further provides for isolated nucleic acids encoding the antibodies of the invention and host cells transformed therewith. The invention yet further provides for diagnostic, prophylactic and therapeutic methods employing the antibodies and nucleic acids of the invention, particularly as a passive immunotherapy agent in infants and the elderly.

公开(公告)号：US20180208915A1

公开(公告)日：2018-07-26

申请号：US15745357

申请日：2016-07-15

Applicant: Daiichi Sankyo Company, Limited

Inventor： Yoshirou Kawaguchi ,  Kensuke Nakamura ,  Yukiko Sekiguchi ,  Mitsuhiro Iwamoto

IPC: C12N9/24 ,  C07K16/32

CPC classification number: C12N9/2402 ,  C07K16/32 ,  C07K2317/41 ,  C12N15/02 ,  C12N15/09 ,  C12P21/02 ,  C12Y302/01096

Abstract: The present invention provides an EndoS mutant enzyme having an amino acid sequence of EndoS D233Q and further having a particular additional mutation and exhibiting a reduced hydrolysis activity, in comparison with the activity of EndoS D233Q, to an N-linked sugar chain (N297-linked sugar chain) linked to Asn at position 297 in IgG and a gene encoding the same.

公开(公告)号：US20180201675A1

公开(公告)日：2018-07-19

申请号：US15816063

申请日：2017-11-17

Applicant: Alderbio Holdings LLC

Inventor： Leon F. Garcia-Martinez ,  Anne Elisabeth Carvalho Jensen ,  Katie Anderson ,  Benjamin H. Dutzar ,  Ethan W. Ojala ,  Brian R. Kovacevich ,  John A. Latham ,  Jeffrey T.L. Smith

IPC: C07K16/24

CPC classification number: C07K16/248 ,  A61K2039/505 ,  C07K2317/24 ,  C07K2317/34 ,  C07K2317/41 ,  C07K2317/51 ,  C07K2317/515 ,  C07K2317/56 ,  C07K2317/565 ,  C07K2317/64 ,  C07K2317/76

Abstract: The present invention is directed to antibodies and fragments thereof and humanized versions thereof having binding specificity for IL-6. Another embodiment of this invention relates to the antibodies described herein, and binding fragments thereof, comprising the sequences of the VH, VL and CDR polypeptides described herein, and the polynucleotides encoding them. The invention also contemplates conjugates of anti-IL-6 antibodies and binding fragments thereof conjugated to one or more functional or detectable moieties. The invention also contemplates methods of making said anti-IL-6 antibodies and binding fragments thereof. Embodiments of the invention also pertain to the use of anti-IL-6 antibodies, and binding fragments thereof, for the diagnosis, assessment and treatment of diseases and disorders associated with IL-6. These antibodies may bind at least one of soluble IL-6, cell surface expressed IL-6, IL-6/IL-6R and/or prevent the association of IL-6 and IL-6R, the association of IL-6/IL-6R and gp130 and or the formation of IL-6/IL-6R/gp130 multimers and thereby inhibit a biological effect associated with any of the foregoing.

公开(公告)号：US20180194846A1

公开(公告)日：2018-07-12

申请号：US15906703

申请日：2018-02-27

Applicant: Novartis AG

Inventor： Catrin Berger ,  Tanja Herrmann ,  Chris Lu ,  Kelly-Ann Sheppard ,  Estelle Trifilieff ,  Stephanie Urlinger

IPC: C07K16/28 ,  A61K45/06 ,  A61K39/395 ,  A61K39/00

CPC classification number: C07K16/2863 ,  A61K39/3955 ,  A61K45/06 ,  A61K2039/505 ,  C07K16/28 ,  C07K2317/21 ,  C07K2317/34 ,  C07K2317/41 ,  C07K2317/52 ,  C07K2317/55 ,  C07K2317/56 ,  C07K2317/565 ,  C07K2317/76 ,  C07K2317/92

Abstract: This disclosure is in the field of anti-Activin receptor IIB (ActRIIB) antibodies. In particular, it relates to the use of said antibodies for treating muscle disorders, such as muscle wasting due to disease or disuse.